Related references
Note: Only part of the references are listed.Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
James B. Wing et al.
IMMUNITY (2019)
Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
Akinori Sasaki et al.
GASTRIC CANCER (2019)
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody
Danbee Ha et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Frederick Arce Vargas et al.
CANCER CELL (2018)
Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy
Mathieu F. Chevalier et al.
EUROPEAN UROLOGY (2018)
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Carsten Krieg et al.
NATURE MEDICINE (2018)
PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells
Chaido Stathopoulou et al.
IMMUNITY (2018)
Hyperprogressive disease: recognizing a novel pattern to improve patient management
Stephane Champiat et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy
Jianmin Zhu et al.
JCI INSIGHT (2018)
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Stephane Champiat et al.
CLINICAL CANCER RESEARCH (2017)
ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori
Hirotsugu Nagase et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei et al.
CELL (2017)
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
Shumei Kato et al.
CLINICAL CANCER RESEARCH (2017)
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy
Takeru Asano et al.
BLOOD (2017)
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Jason D. Fontenot et al.
JOURNAL OF IMMUNOLOGY (2017)
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Takuro Saito et al.
NATURE MEDICINE (2016)
Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model
Baihao Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results
Omid Hamid et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
PD-1 marks dysfunctional regulatory T cells in malignant gliomas
Daniel E. Lowther et al.
JCI INSIGHT (2016)
OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer
Ryan Montler et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2016)
PD-1 Upregulated on Regulatory T Cells during Chronic Virus Infection Enhances the Suppression of CD8+ T Cell Immune Response via the Interaction with PD-L1 Expressed on CD8+ T Cells
Hyo Jin Park et al.
JOURNAL OF IMMUNOLOGY (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Matias E. Valsecchi
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3high regulatory T cells in humans
Makoto Miyara et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
Emanuela Romano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Continuous T Cell Receptor Signals Maintain a Functional Regulatory T Cell Pool
J. Christoph Vahl et al.
IMMUNITY (2014)
Continuous requirement for the TCR in regulatory T cell function
Andrew G. Levine et al.
NATURE IMMUNOLOGY (2014)
FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS
Yawei Liu et al.
NATURE MEDICINE (2014)
An obligate cell-intrinsic function for CD28 in Tregs
Ruan Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
Daisuke Sugiyama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
FOXP3+ regulatory T cells in the human immune system
Shimon Sakaguchi et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
Makoto Miyara et al.
IMMUNITY (2009)
Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation
Yasushi Onishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
How regulatory T cells work
Dario A. A. Vignali et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Induction of FOXP3 expression in naive human CD4+FOXP3- T cells by T-cell receptor stimulation is transforming growth factor-β-dependent but does not confer a regulatory phenotype
Dat Q. Tran et al.
BLOOD (2007)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
An essential role for Scurfin in CD4+CD25+ T regulatory cells
R Khattri et al.
NATURE IMMUNOLOGY (2003)
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
JD Fontenot et al.
NATURE IMMUNOLOGY (2003)
Control of regulatory T cell development by the transcription factor Foxp3
S Hori et al.
SCIENCE (2003)
Share Paper
